Karius, Inc. Announces Data Presentations and Informational Session at ASM Microbe 2017

May 30, 2017

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Karius, Inc., a life sciences company focused on conquering infectious
diseases, today announced that new data on the company’s next-generation
sequencing test will be presented at the American Society for
Microbiology’s Microbe 2017 conference taking place at the Ernest N.
Morial Convention Center June 1 – 5 in New Orleans.

Abstracts from four studies of the Karius Digital Culture™ test will be
presented:

• Detection
  of Nocardia Cyriacigeorgica from a Deep Pulmonary Infection Using a
  Novel Plasma-Based Next Generation Sequencing Assay
  presented
  by Monica Nayakwadi-Singer, M.D.,University of California-San
  Francisco (UCSF) Benioff Children’s Hospital Oakland, on June 3 at
  12:15 p.m. CT in Exhibit Hall D
• Liquid
  Biopsy for Infectious Diseases: Application of a Next-Generation
  Sequencing Cell-Free Plasma Assay to Detect Invasive Fungal Infections
  presented
  byDavid Hong, M.D., medical director, Karius, Inc., on June 3
  at 4:30 p.m. CT in room 207
• The
  SEP-SEQ Trial – A Pilot Study Characterizing the Performance of a
  Novel Plasma Next-Generation Sequencing Assay to Detect Cell-Free
  Microbial DNA in Patients with Sepsis
  presented bySimone Thair, Ph.D., Stanford University Medical Center, on
  June 4 at 12:15 p.m. CT in Exhibit Hall D
• The
  DISCOVER Trial: Application of a Novel Plasma Next-Generation
  Sequencing Assay to Detect Cell-Free Microbial DNA in Stem-Cell
  Transplant Patients
  presented byMonica
  Fung, M.D., UCSF,onJune 4 at 12:15 p.m.
  CT in Exhibit Hall D

Karius will also be presenting “Beyond the Panel,” an informational
session highlighting the company’s technology platform and how it has
been used by physicians to detect a variety of difficult-to-diagnose
pathogens. The presentation will take place Saturday, June 3 at 1:30
p.m. CT in the Industry and Science Showcase Theater A.

About the Karius Digital Culture™ Test

The Karius Digital Culture™ test applies advanced sequencing and
analytics for the broad and rapid detection of microbial cell-free DNA
through a standard blood draw. Unlike conventional culture and panel
testing methods that test for a narrow range of pathogens, the Karius
test can detect more than 1,250 pathogens. Through Karius’
CAP-accredited and CLIA-certified laboratory service, the test empowers
doctors to diagnose infections, provide more targeted treatment, and
spare patients the pain and risks of invasive biopsies.

About Karius, Inc.

Karius is a life sciences company focused on conquering infectious
diseases through the innovative use of next-generation sequencing to
analyze microbial cell-free DNA. The company’s genomics platform
delivers unprecedented insight into the microbial landscape, providing
clinicians with a comprehensive test capable of identifying more than a
thousand pathogens directly from blood and helping industry accelerate
drug development. For more information visit kariusdx.com
and follow us on Twitter at @kariusdx.

Contacts

Karius, Inc.
Krysta Pellegrino, 650-255-6142
media@kariusdx.com
or
Jessica
Volchok, 310-849-7985
media@kariusdx.com